Zorubicin

Zorubicin

SCHEMBL4759324

CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1c(O)cccc1C3=O.COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(/C(C)=N/NC(=O)c1ccccc1)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 10/20 0.79
▸ THRB P10828 10/20 0.79
▸ KMT2A Q03164 10/20 0.79
▸ BLM P54132 9/20 0.79
▸ RECQL P46063 8/20 0.79
▸ MAPT P10636 7/20 0.79
▸ SMN1; SMN2 Q16637 7/20 0.79
▸ BRCA1 P38398 6/20 0.79
▸ TDP1 Q9NUW8 6/20 0.79
▸ HIF1A Q16665 6/20 0.79
▸ USP2 O75604 5/20 0.79
▸ HTT P42858 5/20 0.79
▸ MAPK1 P28482 5/20 0.79
▸ TOP2A P11388 5/20 0.79
▸ CYP3A4 P08684 4/20 0.79
▸ CHRM1 P11229 4/20 0.79
▸ KDM4E B2RXH2 4/20 0.79
▸ ALDH1A1 P00352 4/20 0.79
▸ CYP1A2 P05177 3/20 0.79
▸ APEX1 P27695 3/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zorubicin SCHEMBL28142133 0.97 MEN1 (0.82) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL8232 0.96 S100A4 (0.84) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL13840951 0.96 S100A4 (0.84) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL8231 0.96 S100A4 (0.84) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL1651187 0.96 S100A4 (0.84) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL29352324 0.96 S100A4 (0.84) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL29617182 0.95 S100A4 (0.83) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL4023 0.95 S100A4 (0.83) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL4024 0.95 S100A4 (0.83) MEN1THRBKMT2ABLMRECQL
Zorubicin SCHEMBL27835878 0.94 S100A4 (0.81) MEN1THRBKMT2ABLMRECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080247987-A1 Block Copolymer Compositions and Uses Thereof ANGIOTECH INTERNATIONAL AG (CH) 2008-10-09 — — US disclosed
US-20080124400-A1 Microparticles With High Loadings Of A Bioactive Agent ANGIOTECH INTERNATIONAL AG (CH) 2008-05-29 — — US disclosed
EP-1909774-A2 BLOCK COPOLYMER COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2008-04-16 — — EP disclosed
WO-2007019439-A2 BLOCK COPOLYMER COMPOSITIONS AND USES THEREOF ANGIOTECH INTERNATIONAL AG (CH) 2007-02-15 — — WO disclosed
US-20070026043-A1 Medical devices combined with diblock copolymer compositions ANGIOTECH INTERNATIONAL AG (CH) 2007-02-01 — — US disclosed
CN-1878514-A Soft tissue implants and anti-scarring agents ANGIOTECH INT AG (CH) 2006-12-13 — — CN disclosed
WO-2006002365-A2 MICROPARTICLES WITH HIGH LOADINGS OF A BIOACTIVE AGENT ANGIOTECH INTERNATIONAL AG (CH) 2006-01-05 — — WO disclosed
WO-2005007129-A2 TOPICAL FORMULATIONS WITH BIOACTIVE COMPONENTS ANGIOTECH INTERNATIONAL AG (CH) 2005-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080247987-A1 Block Copolymer Compositions and Uses Thereof ERBB3, LRBA, PPIB MEN1 3461/4885THRB 1535/4885KMT2A 4666/4885
US-20080124400-A1 Microparticles With High Loadings Of A Bioactive Agent FGF23, BMP2, BMP6 MEN1 1184/4885THRB 4173/4885KMT2A 4676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback